Potentially Promising Treatment for FOP
We are pleased to share a few exciting updates on our ongoing work to help improve the lives of people with FOP.
Regeneron has been investigating FOP for two decades and is currently focused on studying REGN2477, a potentially promising investigational treatment for FOP that was granted orphan drug designation status from the U.S. Food and Drug Administration and the European Medicines Agency. REGN2477 is a human monoclonal antibody that blocks Activin A, a protein discovered by our scientists to be a key factor in the development of heterotopic ossification in a mouse model of FOP.
Earlier this year, we completed our first-in-human study to evaluate the safety and tolerability of REGN2477 across a wide range of doses. We convened our first Patient Advisory Board meeting with 12 members of the FOP community to gain important first-hand insights on the unique challenges faced by individuals living with FOP. The discussion helped us better understand the multi-faceted needs of the FOP population, and we are incorporating these learnings into the design of the Phase 2 study in patients planned for this year.
Regeneron is a leading U.S. biotechnology company that has been run by physician-scientists for nearly 30 years. We are dedicated to developing life-changing medicines for patients with serious medical conditions. We have thus far developed four approved treatments; all through original Regeneron research. Some of these medicines are for patients with relatively common conditions such as certain blindness-causing diseases. Others are for patients with less common genetic conditions, such as heterozygous familial hypercholesterolemia or Cryopyrin-Associated Periodic Syndromes (CAPS), a set of rare, yet closely related, auto-inflammatory diseases. In addition to FOP, we currently have investigational medicines in development for rheumatoid arthritis, asthma, atopic dermatitis, cancer and Ebola. Please stay tuned for updates on our progress and visit www.regeneron.com to learn more.
